Studies blood DNA tests in people with spread cancer
Observes treatments and blood DNA tests that track response in metastatic cancer.
Key facts
- Who runs it
- Gene Solutions
- Where
- Ho Chi Minh City, VietnamSee the site
- Trial code
- Registry title
- Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 9 Apr 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Record updated
- 16 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic (stage IV) cancer of the lung, colon or rectum, breast or stomach, or cancer of unknown origin, who have already had K4Care testing.
- Sex
- All sexes can join.
- Disease stage
- Metastatic or progressing stage IV cancer, confirmed by pathology and imaging. Lung, colorectal, breast, gastric or cancer of unknown primary origin.
- Earlier treatment
- Must have had K4Care testing of the tumor tissue before joining.
- Biomarker or test result
- K4Care testing of tumor tissue (FFPE) to find mutations, with consent to use the sequencing data.
Main reasons for not taking part
- No earlier K4Care testing
- Early-stage cancer
- Blood cancer (hematologic malignancy)
- Refusal to give clinical information or blood samples
- Refusal to take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Pathological and imaging confirmation of metastatic or progressive stage IV cancer
- Consent to the use of their clinical data
- Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin
- Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data
Who cannot take part
- Absence of prior K4Care testing
- Diagnosis of early-stage cancer or hematologic malignancy
- Refusal to participate in the study
- Refusal to provide clinical information or blood samples
Where in Vietnam
- Medical Genetics InstituteHo Chi Minh City, VietnamContact: Lan N Tu, PhD.Taking people
About the trial
What the trial wants to find out
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA (ctDNA) Assays in Monitoring Treatment Response in Patients With Metastatic Cancer Undergoing K4Care Testing
- Plain-language title
- Studies blood DNA tests in people with spread cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 July 2025